Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

U.S. FDA to Review Philip Morris International’s IQOS Risk Modification Renewal Application in October

Jul.30.2025
U.S. FDA to Review Philip Morris International’s IQOS Risk Modification Renewal Application in October
The U.S. FDA will review Philip Morris International’s renewal application for five IQOS products' modified risk status at an October 7 TPSAC meeting, evaluating whether they still meet the required standards.

Key points:

 

·Key Event: The US FDA will hold a TPSAC meeting on October 7th to discuss the renewal application for the IQOS product's "reduced risk" designation. 

 

·Products involved include Marlboro Amber, Green Mint, Blue Mint heat-not-burn pods, as well as the IQOS 2.4 and 3.0 systems and chargers. 

 

·Evaluation Focus: The meeting will focus on scientific evidence to determine whether the products continue to meet the "reduced risk" standard. 

 

·Public Participation: The meeting is open to the public and can be watched via live stream online. The public can submit written comments or apply to speak.

 

 

【2Firsts News Flash】According to an announcement on the FDA's official website on July 29th, the U.S. Food and Drug Administration (FDA) has issued a Federal Register notice declaring that the Tobacco Products Scientific Advisory Committee (TPSAC) meeting is scheduled to be held on October 7, 2025. The meeting will discuss the renewal of the "Modified Risk Authorization" for products from Philip Morris International (PMI) (Philip Morris Products S.A.).

 

·Marlboro Amber HeatSticks

·Marlboro Green Menthol HeatSticks

·Marlboro Blue Menthol HeatSticks 

·The IQOS system includes the IQOS 2.4 main unit and charger, as well as the IQOS 3.0 main unit and charger.

 

The FDA initially authorized the sale of these products through the Pre-Market Tobacco Product Application (PMTA) pathway in 2019 and 2020. Subsequently, in 2020 and 2022, the FDA issued "modified risk orders," allowing Philip Morris International (PMI) to market these five IQOS heated tobacco products as "reduced risk tobacco products" based on information that they reduce exposure to harmful substances.

 

Based on the current available evidence:

 

·The IQOS system heats tobacco without burning it, significantly reducing the production of harmful and potentially harmful chemicals. 

 

·Scientific research shows that switching completely from traditional cigarettes to the IQOS system can significantly reduce the body's exposure to harmful or potentially harmful chemicals.

 

After evaluating the scientific evidence provided by applicants, the FDA issued "risk reduction orders" to ensure that information about reducing exposure risks is supported by scientific evidence and easily understandable to consumers. These "risk reduction orders" require companies to conduct post-market surveillance and studies to determine if the authorization for "reduced risk tobacco products" should continue. According to the law, the validity of these orders is fixed as stipulated in the authorization and not permanent.

 

In order to continue marketing these products as "reduced risk tobacco products" after the authorization period expires, the company submitted a renewal application to the FDA. On May 9, 2024, the FDA conducted a scientific review of these applications and made the application materials available online for public comment. According to the law, the FDA must disclose the application materials to the public and submit the applications to TPSAC. The discussion at the TPSAC meeting will focus on whether the scientific standards for marketing these products as "reduced risk tobacco products" continue to be met.

 

The TPSAC meeting will be open to the public and held at the White Oak campus of the FDA in Silver Spring, Maryland. Additionally, the public can watch the meeting via live webcast with subtitles and recordings available. Visit the event page for more information on attending in person or online.

 

Stakeholders can provide data, information, or opinions on issues under consideration by the committee in oral or written form. Written comments must be submitted to the contacts listed in the Federal Register notice by September 25, 2025. Public oral comments will be scheduled for October 7, 2025, from 1:00 to 2:00 PM (Eastern Time). Those wishing to make oral comments must notify the contacts by September 11, 2025, and provide a brief statement describing the nature of the evidence or arguments they wish to present, the names and email addresses of anticipated participants, and whether they prefer to speak online or in person. For more information, please refer to the Federal Register notice.

 

Furthermore, the FDA has reissued application documents related to the renewal of the existing authorization for the IQOS product as a "reduced risk tobacco product." These reissued documents include information that was previously redacted. The application materials that were redacted in accordance with applicable laws and regulations can be found on the FDA website. The FDA will consider all available information, including public comments and recommendations from TPSAC, before making a final decision on the application for the "reduced risk tobacco product.

 

References:
[1] Advisory Committee Meeting Scheduled on Modified Risk Tobacco Product Renewal Applications for IQOS Products
Also Read:
[1] FDA Extends Swedish Match U.S.A. Inc. General Snus MRTP Order

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Regulation Shift：Policy Updates and Market Impact
China Tobacco Regulation Shift：Policy Updates and Market Impact
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
HM Revenue & Customs put the UK's Vaping Products Duty and Vaping Duty Stamps Scheme into effect on October 1. All vaping liquids manufactured in or imported into the UK are now subject to duty at £2.20 per 10ml, regardless of nicotine content. The stamp regime will introduce digital functionality designed to provide traceability throughout the supply chain, with approved manufacturers, importers and warehousekeepers required to report product movements and retailers and consumers eventually able to scan stamps to verify authenticity. China exported $177 million of vape-related products to the UK in August, up 51.4% year over year, increasing the significance of the new compliance regime for China's Shenzhen-centered vape supply chain.
Regulations
Oct.04
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Related Topics
News Regulation
Related Read
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2026 2FIRSTS. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland.
English
English
中文